BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23135254)

  • 21. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
    Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
    Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
    Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
    Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
    Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
    Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model.
    Sokolova EA; Shilova ON; Kiseleva DV; Schulga AA; Balalaeva IV; Deyev SM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096563
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
    Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.
    Pradelli E; Karimdjee-Soilihi B; Michiels JF; Ricci JE; Millet MA; Vandenbos F; Sullivan TJ; Collins TL; Johnson MG; Medina JC; Kleinerman ES; Schmid-Alliana A; Schmid-Antomarchi H
    Int J Cancer; 2009 Dec; 125(11):2586-94. PubMed ID: 19544560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells.
    Zhao J; Zhang LH; Jia LT; Zhang L; Xu YM; Wang Z; Yu CJ; Peng WD; Wen WH; Wang CJ; Chen SY; Yang AG
    J Biol Chem; 2004 May; 279(20):21343-8. PubMed ID: 15004021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
    Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
    Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma.
    Liao D; Zhong L; Yin J; Zeng C; Wang X; Huang X; Chen J; Zhang H; Zhang R; Guan XY; Shuai X; Sui J; Gao S; Deng W; Zeng YX; Shen JN; Chen J; Kang T
    Nat Cell Biol; 2020 Jul; 22(7):868-881. PubMed ID: 32483387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.
    Green DS; Husain SR; Johnson CL; Sato Y; Han J; Joshi B; Hewitt SM; Puri RK; Zoon KC
    Immunotherapy; 2019 Apr; 11(6):483-496. PubMed ID: 30860437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription.
    Chen F; Mo J; Zhang L
    Tumour Biol; 2016 Oct; 37(10):13403-13412. PubMed ID: 27460090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biotechnological and gene therapeutic strategies in cancer treatment.
    Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
    Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.
    Wang L; Liu B; Schmidt M; Lu Y; Wels W; Fan Z
    Prostate; 2001 Apr; 47(1):21-8. PubMed ID: 11304726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway.
    Park KR; Yun HM; Quang TH; Oh H; Lee DS; Auh QS; Kim EC
    Oncotarget; 2016 Feb; 7(6):6960-71. PubMed ID: 26755649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
    Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
    Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.